Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$18.51
-0.78-4.04%
At close: -
$18.50
-0.01-0.05%
After Hours: 5:23 PM EDT
Comments
Loading...
AnaptysBio Analyst Ratings and Price Targets | NASDAQ:ANAB | Benzinga
AnaptysBio Inc has a consensus price target of $41.17 based on the ratings of 15 analysts. The high is $80 issued by Piper Sandler on February 16, 2024. The low is $20 issued by Truist Securities on December 18, 2024. The 3 most-recent analyst ratings were released by JP Morgan, HC Wainwright & Co., and Wells Fargo on March 5, 2025, March 4, 2025, and February 13, 2025, respectively. With an average price target of $38.33 between JP Morgan, HC Wainwright & Co., and Wells Fargo, there's an implied 107.21% upside for AnaptysBio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Wells Fargo
Wedbush
Truist Securities
1calculated from analyst ratings
Analyst Ratings for AnaptysBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/05/2025 | Buy Now | 127.03% | JP Morgan | Anupam Rama57% | $36 → $42 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | 18.92% | HC Wainwright & Co. | Emily Bodnar38% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/13/2025 | Buy Now | 175.68% | Wells Fargo | Derek Archila56% | $40 → $51 | Maintains | Overweight | Get Alert |
| 02/07/2025 | Buy Now | 116.22% | Wedbush | David Nierengarten60% | $40 → $40 | Maintains | Outperform | Get Alert |
| 02/04/2025 | Buy Now | — | Wolfe Research | Andy Chen36% | — | Initiates | → Outperform | Get Alert |
| 02/04/2025 | Buy Now | 2.7% | HC Wainwright & Co. | Emily Bodnar38% | $19 → $19 | Reiterates | Neutral → Neutral | Get Alert |
| 12/19/2024 | Buy Now | 94.59% | JP Morgan | Anupam Rama57% | $66 → $36 | Maintains | Overweight | Get Alert |
| 12/18/2024 | Buy Now | 8.11% | Truist Securities | John Lee1% | $30 → $20 | Maintains | Hold | Get Alert |
| 12/12/2024 | Buy Now | 116.22% | Wells Fargo | Derek Archila56% | $56 → $40 | Maintains | Overweight | Get Alert |
| 12/12/2024 | Buy Now | 94.59% | Guggenheim | Yatin Suneja47% | $90 → $36 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/02/2024 | Buy Now | — | BTIG | Julian Harrison40% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/12/2024 | Buy Now | 256.76% | JP Morgan | Anupam Rama57% | $75 → $66 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | 181.08% | HC Wainwright & Co. | Emily Bodnar38% | $55 → $52 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 197.3% | HC Wainwright & Co. | Emily Bodnar38% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2024 | Buy Now | 78.38% | UBS | Eliana Merle43% | $23 → $33 | Maintains | Neutral | Get Alert |
| 10/21/2024 | Buy Now | 386.49% | Guggenheim | Yatin Suneja47% | $75 → $90 | Maintains | Buy | Get Alert |
| 09/26/2024 | Buy Now | 127.03% | Wedbush | David Nierengarten60% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 62.16% | Truist Securities | John Lee1% | $20 → $30 | Maintains | Hold | Get Alert |
| 08/14/2024 | Buy Now | 197.3% | HC Wainwright & Co. | Emily Bodnar38% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 305.41% | JP Morgan | Anupam Rama57% | $69 → $75 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 197.3% | HC Wainwright & Co. | Emily Bodnar38% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 197.3% | HC Wainwright & Co. | Emily Bodnar38% | → $55 | Initiates | → Buy | Get Alert |
| 07/19/2024 | Buy Now | 272.97% | JP Morgan | Anupam Rama57% | $29 → $69 | Upgrade | Neutral → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 83.78% | Wedbush | David Nierengarten60% | → $34 | Reiterates | Outperform → Outperform | Get Alert |
| 04/16/2024 | Buy Now | 154.05% | Leerink Partners | David Risinger73% | → $47 | Initiates | → Outperform | Get Alert |
| 04/11/2024 | Buy Now | 202.7% | Wells Fargo | Derek Archila56% | → $56 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 51.35% | JP Morgan | Anupam Rama57% | $30 → $28 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | — | Wedbush | David Nierengarten60% | $20 → $34 | Upgrade | Neutral → Outperform | Get Alert |
| 02/26/2024 | Buy Now | 197.3% | BTIG | Julian Harrison40% | → $55 | Initiates | → Buy | Get Alert |
| 02/21/2024 | Buy Now | 170.27% | Stifel | Alex Schwartz43% | → $50 | Initiates | → Buy | Get Alert |
| 02/16/2024 | Buy Now | 332.43% | Piper Sandler | Yasmeen Rahimi56% | → $80 | Initiates | → Overweight | Get Alert |
| 11/29/2023 | Buy Now | 8.11% | Wedbush | David Nierengarten60% | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 11/03/2023 | Buy Now | 8.11% | Wedbush | David Nierengarten60% | $18 → $20 | Maintains | Neutral | Get Alert |
| 11/02/2023 | Buy Now | 13.51% | UBS | Eliana Merle43% | $28 → $21 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 40.54% | Wedbush | David Nierengarten60% | $29 → $26 | Maintains | Neutral | Get Alert |
| 05/22/2023 | Buy Now | 62.16% | JP Morgan | Anupam Rama57% | $31 → $30 | Upgrade | Underweight → Neutral | Get Alert |
| 05/12/2023 | Buy Now | 56.76% | Wedbush | David Nierengarten60% | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2023 | Buy Now | 143.24% | Guggenheim | Yatin Suneja47% | $44 → $45 | Maintains | Buy | Get Alert |
| 04/12/2023 | Buy Now | 67.57% | JP Morgan | Anupam Rama57% | $32 → $31 | Maintains | Underweight | Get Alert |
| 01/06/2023 | Buy Now | — | Raymond James | Timur Ivannikov30% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/18/2022 | Buy Now | 72.97% | JP Morgan | Anupam Rama57% | $24 → $32 | Maintains | Underweight | Get Alert |
| 11/09/2022 | Buy Now | 105.41% | Raymond James | Steven Seedhouse58% | $30 → $38 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | — | Guggenheim | Yatin Suneja47% | — | Upgrade | Neutral → Buy | Get Alert |
| 09/19/2022 | Buy Now | 89.19% | HC Wainwright & Co. | Gobind Singh20% | → $35 | Assumes | → Buy | Get Alert |
| 09/13/2022 | Buy Now | 51.35% | Truist Securities | John Lee1% | $50 → $28 | Downgrade | Buy → Hold | Get Alert |
| 09/01/2022 | Buy Now | 89.19% | Raymond James | Steven Seedhouse58% | → $35 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for AnaptysBio (ANAB) stock?
The latest price target for AnaptysBio (NASDAQ:ANAB) was reported by JP Morgan on March 5, 2025. The analyst firm set a price target for $42.00 expecting ANAB to rise to within 12 months (a possible 127.03% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AnaptysBio (ANAB)?
The latest analyst rating for AnaptysBio (NASDAQ:ANAB) was provided by JP Morgan, and AnaptysBio maintained their overweight rating.
When was the last upgrade for AnaptysBio (ANAB)?
The last upgrade for AnaptysBio Inc happened on July 19, 2024 when JP Morgan raised their price target to $69. JP Morgan previously had a neutral for AnaptysBio Inc.
When was the last downgrade for AnaptysBio (ANAB)?
The last downgrade for AnaptysBio Inc happened on December 11, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for AnaptysBio Inc.
When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.
Is the Analyst Rating AnaptysBio (ANAB) correct?
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a maintained with a price target of $36.00 to $42.00. The current price AnaptysBio (ANAB) is trading at is $18.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.